ECTRIMS 2022: Use of Some Disease-Modifying Therapies in Multiple Sclerosis Associated With Increased Risk for COVID-19
Fingolimod and ocrelizumab may increase hospitalizations and mortality for COVID-19-vaccinated people with multiple sclerosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.